Dosimetric verification of stereotactic body radiotherapy treatment plan via ArcCHECK-3DVH system.
10.11817/j.issn.1672-7347.2021.200093
- Author:
Shulin CHENG
1
;
Dongyong SHAN
2
;
Ke CAO
3
;
Shizhen BIN
3
;
Junjun ZHANG
3
;
Tian TANG
3
Author Information
1. Department of Oncology, Third Xiangya Hospital, Central South University, Changsha 410013, China. chengshulin2007@126.com.
2. Department of Oncology, Third Xiangya Hospital, Central South University, Changsha 410013, China. dandongyong@126.com.
3. Department of Oncology, Third Xiangya Hospital, Central South University, Changsha 410013, China.
- Publication Type:Journal Article
- Keywords:
ArcCHECK-3DVH system;
dose verification;
stereotactic body radiotherapy
- MeSH:
Humans;
Phantoms, Imaging;
Quality Assurance, Health Care;
Radiometry;
Radiosurgery;
Radiotherapy Dosage;
Radiotherapy Planning, Computer-Assisted;
Radiotherapy, Intensity-Modulated
- From:
Journal of Central South University(Medical Sciences)
2021;46(5):475-480
- CountryChina
- Language:English
-
Abstract:
OBJECTIVES:To study the feasibility of ArcCHECK-3DVH system in dosimetric verification for stereotactic body radiaotherapy (SBRT) with flattening filter free (FFF) model.
METHODS:SBRT treatment plans for 57 patients were introduced into ArcCHECK phantom and recalculated. The calculated dose distribution of treatment planning system and the measured dose distribution of ArcCHECK phantom were compared by γ analysis. Then the 3 dimensional dose distribution of target and organs at risk was reconstructed by 3DVH software. The reconstructed dose and calculated dose with treatment planning system (TPS) were compared, and the dose volume γ pass rate and deviation of dose volume parameters to the target and organs at risk were quantitatively valuated.
RESULTS:Based on the threshold criteria (3%, 3 mm, 10%), namely the deviation of measuring points between the planned value and the measured value was less than 3%, and the proportion of points with similar values in the plane or sphere with the center of the point and the radius of 3 mm was 10%, the relative and absolute dose pass rates of SBRT treatment plans in ArcCHECK system via γ analysis were greater than 95%. Based on the stricter threshold criteria (2%, 2 mm, 10%), the relative and absolute dose pass rates of SBRT treatment plan in ArcCHECK system via γ analysis were about 93%. In 3DVH dose verification, the γ pass rate of target and organs at risk was exceed 97%, and the deviations in 3DVH of the target and organs at risk were less than ±5%.
CONCLUSIONS:The ArcCHECK-3DVH system in dose verification can provide more comprehensive dose distribution information to reasonably evaluate the SBRT plan, with more significance for guiding clinical treatment.
